Joel Naor MD, MSc, MBA, has partaken in retinal drug development since the inception of the retinal disease drug market. He has a uniquely deep and broad development perspective with a view towards commercialization. His experience encompasses photosensitizers, small molecules, biologics, and drug delivery platforms for a broad spectrum of indications that includes Wet and Dry AMD, Diabetic Retinopathy, Retinal Vein Occlusion, and Posterior Uveitis. Joel served as the VP, Clinical Research, Ophthalmology, for Stem Cells Inc. experimenting with adult Human CNS stem cells for the treatment of Dry AMD. Currently, Joel is the VP, Clinical Science and Development Operations for Kodiak Sciences Inc., a retinal medicines development company that merges the fields of biologics and chemistry based therapies with an antibody biopolymer product platform.